Letters to the Editor

KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications

Institute of Human Genetics, Polish Academy of Sciences, Poznań
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Department of Systems Biology and Engineering and Biotechnology Centre, Silesian University of Technology, Gliwice
Leukemia Therapy Resistance Laboratory, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent
Institute of Human Genetics, Polish Academy of Sciences, Poznań
The Student Scientific Society of Poznan University of Medical Sciences, Poznań
Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin
Department of Microbiology and Immunology, Medical University of Silesia, Zabrze, Poland; Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze
Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze
Department of Genetic Predisposition to Cancer, Medical University of Lodz, Lodz
Department of Pediatric Oncology, Hematology and Transplantology, Institute of Pediatrics, Poznań University of Medical Sciences, Poznań
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Leukemia Therapy Resistance Laboratory, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Haematologica Early view Aug 13, 2026 https://doi.org/10.3324/haematol.2026.300620